{
    "nctId": "NCT04524000",
    "briefTitle": "Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer",
    "officialTitle": "A Phase II Open-label, 2-Part, Multi-center Study of BYL719 (Alpelisib) in Combination With Fulvestrant for Men and Postmenopausal Women With PIK3CA Mutation Hormone Receptor (HR) Positive, HER2-negative, Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor (AI) Treatment in Japan",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Advanced Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 24,
    "primaryOutcomeMeasure": "[Part 1] The incidence of Dose Limiting Toxicities (DLTs) of alpelisib in combination with fulvestrant",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Japanese man or postmenopausal woman\n* Participant has adequate tumor tissue for the analysis of PIK3CA mutational status by a Novartis designated laboratory.\n* Participant has identified PIK3CA mutation (as determined by a Novartis designated laboratory)\n* Participant has a histologically and/or cytologically confirmed diagnosis of ER+ and/or PgR+ breast cancer by local laboratory\n* Participant has HER2-negative breast cancer defined as a negative in situ hybridization test or an IHC status of 0, 1+ or 2+. If IHC is 2+, a negative in situ hybridization (FISH, CISH or SISH) test is required by local laboratory testing\n* Participant has measurable disease, i.e., at least one measurable lesion as per RECIST 1.1\n* Participant has advanced breast cancer\n* Participant has ECOG performance status 0 or 1\n\nExclusion Criteria:\n\n* Participant with symptomatic visceral disease or any disease burden that makes the participant ineligible for endocrine therapy per the investigator's best judgment\n* Participant has received prior treatment;\n* with chemotherapy (except for neoadjuvant/ adjuvant chemotherapy), fulvestrant, any PI3K, mTOR or AKT inhibitor for Cohort 1 and 3\n* with chemotherapy (except for neoadjuvant/ adjuvant chemotherapy), fulvestrant, any PI3K, mTOR, AKT inhibitor or CDK 4/6 inhibitor for Cohort 2\n* Participant has a known hypersensitivity to alpelisib or fulvestrant, or to any of the excipients of alpelisib or fulvestrant\n* Participant with inflammatory breast cancer at screening\n* Participant is concurrently using other anti-cancer therapy\n* Participant has had surgery within 14 days prior to starting study drug or has not recovered from major side effects\n* Participant with an established diagnosis at screening of diabetes mellitus type I or not controlled type II (based on FPG and HbA1c)\n* Participant has currently documented pneumonitis /interstitial lung disease\n* History of acute pancreatitis within 1 year of screening or past medical history of chronic pancreatitis\n* Participant with unresolved osteonecrosis of the jaw\n* Participant has a history of severe cutaneous reactions\n\nOther protocol-defined inclusion/exclusion criteria may apply",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}